Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Increased blood pressure in mice lacking cytochrome P450 2J5.

Athirakul K, Bradbury JA, Graves JP, DeGraff LM, Ma J, Zhao Y, Couse JF, Quigley R, Harder DR, Zhao X, Imig JD, Pedersen TL, Newman JW, Hammock BD, Conley AJ, Korach KS, Coffman TM, Zeldin DC.

FASEB J. 2008 Dec;22(12):4096-108. doi: 10.1096/fj.08-114413. Epub 2008 Aug 20.

2.

Molecular cloning, enzymatic characterization, developmental expression, and cellular localization of a mouse cytochrome P450 highly expressed in kidney.

Ma J, Qu W, Scarborough PE, Tomer KB, Moomaw CR, Maronpot R, Davis LS, Breyer MD, Zeldin DC.

J Biol Chem. 1999 Jun 18;274(25):17777-88.

3.

Regulation of mouse renal CYP2J5 expression by sex hormones.

Ma J, Graves J, Bradbury JA, Zhao Y, Swope DL, King L, Qu W, Clark J, Myers P, Walker V, Lindzey J, Korach KS, Zeldin DC.

Mol Pharmacol. 2004 Mar;65(3):730-43.

4.

Role of cytochrome P450 epoxygenase in regulating renal membrane transport and hypertension.

Capdevila J, Wang W.

Curr Opin Nephrol Hypertens. 2013 Mar;22(2):163-9. doi: 10.1097/MNH.0b013e32835d911e. Review.

5.

Angiotensin II sensitivity of afferent glomerular arterioles in endothelin-1 transgenic mice.

Patzak A, Bontscho J, Lai E, Kupsch E, Skalweit A, Richter CM, Zimmermann M, Thöne-Reineke C, Joehren O, Godes M, Steege A, Hocher B.

Nephrol Dial Transplant. 2005 Dec;20(12):2681-9. Epub 2005 Sep 27.

PMID:
16188896
6.

Role of epoxyeicosatrienoic acids (EETs) in mediation of dopamine's effects in the kidney.

Zhang MZ, Wang Y, Yao B, Gewin L, Wei S, Capdevila JH, Harris RC.

Am J Physiol Renal Physiol. 2013 Dec 15;305(12):F1680-6. doi: 10.1152/ajprenal.00409.2013. Epub 2013 Oct 23.

7.
8.

Role of cytochrome P450-dependent arachidonic acid metabolites in liver physiology and pathophysiology.

Sacerdoti D, Gatta A, McGiff JC.

Prostaglandins Other Lipid Mediat. 2003 Oct;72(1-2):51-71. Review.

PMID:
14626496
10.

A peroxisome proliferator-activated receptor-alpha activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury.

Muller DN, Theuer J, Shagdarsuren E, Kaergel E, Honeck H, Park JK, Markovic M, Barbosa-Sicard E, Dechend R, Wellner M, Kirsch T, Fiebeler A, Rothe M, Haller H, Luft FC, Schunck WH.

Am J Pathol. 2004 Feb;164(2):521-32.

11.

Cytochrome P450 metabolites of arachidonic acid in the control of renal function.

Maier KG, Roman RJ.

Curr Opin Nephrol Hypertens. 2001 Jan;10(1):81-7. Review.

PMID:
11195057
12.

Kidney CYP450 enzymes: biological actions beyond drug metabolism.

Zhao X, Imig JD.

Curr Drug Metab. 2003 Feb;4(1):73-84. Review.

PMID:
12570747
14.

Renal cytochrome P-450-arachidonic acid metabolism: localization and hormonal regulation in SHR.

Omata K, Abraham NG, Schwartzman ML.

Am J Physiol. 1992 Apr;262(4 Pt 2):F591-9.

PMID:
1566872
15.

Superoxide dismutase 1 limits renal microvascular remodeling and attenuates arteriole and blood pressure responses to angiotensin II via modulation of nitric oxide bioavailability.

Carlström M, Lai EY, Ma Z, Steege A, Patzak A, Eriksson UJ, Lundberg JO, Wilcox CS, Persson AE.

Hypertension. 2010 Nov;56(5):907-13. doi: 10.1161/HYPERTENSIONAHA.110.159301. Epub 2010 Sep 27.

16.

p47(phox) is required for afferent arteriolar contractile responses to angiotensin II and perfusion pressure in mice.

Lai EY, Solis G, Luo Z, Carlstrom M, Sandberg K, Holland S, Wellstein A, Welch WJ, Wilcox CS.

Hypertension. 2012 Feb;59(2):415-20. doi: 10.1161/HYPERTENSIONAHA.111.184291. Epub 2011 Dec 19.

17.

Possible role of P-450 metabolite of arachidonic acid in vasodilator mechanism of angiotensin II type 2 receptor in the isolated microperfused rabbit afferent arteriole.

Arima S, Endo Y, Yaoita H, Omata K, Ogawa S, Tsunoda K, Abe M, Takeuchi K, Abe K, Ito S.

J Clin Invest. 1997 Dec 1;100(11):2816-23.

18.

Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice.

Lee CR, Imig JD, Edin ML, Foley J, DeGraff LM, Bradbury JA, Graves JP, Lih FB, Clark J, Myers P, Perrow AL, Lepp AN, Kannon MA, Ronnekleiv OK, Alkayed NJ, Falck JR, Tomer KB, Zeldin DC.

FASEB J. 2010 Oct;24(10):3770-81. doi: 10.1096/fj.10-160119. Epub 2010 May 21.

19.

Role of cytochrome P450 metabolites of arachidonic acid in hypertension.

Sarkis A, Roman RJ.

Curr Drug Metab. 2004 Jun;5(3):245-56. Review.

PMID:
15180494
20.

Adenosine A₁-receptor deficiency diminishes afferent arteriolar and blood pressure responses during nitric oxide inhibition and angiotensin II treatment.

Gao X, Patzak A, Sendeski M, Scheffer PG, Teerlink T, Sällström J, Fredholm BB, Persson AE, Carlström M.

Am J Physiol Regul Integr Comp Physiol. 2011 Dec;301(6):R1669-81. doi: 10.1152/ajpregu.00268.2011. Epub 2011 Oct 5.

Supplemental Content

Support Center